SCHEMBL5498067

SCHEMBL5498067

Cc1ccc(CSCC(CN)CC(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.45
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
CYP2D6 P10635 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CACNA2D1 P54289 2/20 0.40
CACNB3 P54284 1/20 0.40
CACNA1C Q13936 1/20 0.40
PGR P06401 1/20 0.40
ADRA1A P35348 1/20 0.40
HTR2B P41595 1/20 0.40
CACNA2D2 Q9NY47 1/20 0.40
IDO1 P14902 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5500143 0.79 IDO1 (0.42) CYP2D6CYP1A2CYP2C19IDO1
SCHEMBL20395348 0.76 CYP2C19 (0.55) ACEPPARGPPARACYP2C19LMNA
SCHEMBL8332405 0.76 HTT (0.61) CYP2D6CYP1A2CYP2C19LMNAALDH1A1
SCHEMBL919742 0.75 KIF11 (0.56) ACEPPARGPPARALMNAALDH1A1
SCHEMBL1158094 0.75 KIF11 (0.56) ACEPPARGPPARALMNAALDH1A1
SCHEMBL1158095 0.75 KIF11 (0.56) ACEPPARGPPARALMNAALDH1A1
Hydrochloric Acid SCHEMBL27713539 0.74 KIF11 (0.55) ACEPPARGPPARALMNAALDH1A1
Hydrochloric Acid SCHEMBL7323852 0.74 KIF11 (0.55) ACEPPARGPPARALMNAALDH1A1
SCHEMBL25765595 0.72 IDO1 (0.46) ACECYP2D6CYP1A2CYP2C19ALDH1A1
SCHEMBL6741702 0.72 CYP2C19 (0.48) CYP2C19LMNAALDH1A1IDO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0937032-B1 SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS WARNER LAMBERT CO (US) 2007-05-09 EP claimed
US-6153650-A TREATMENT OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, NEUROPATHOLOGICAL DISORDERS, INFLAMMATION, AND GASTROINTESTINAL DAMAGE. WARNER-LAMBERT COMPANY (US) 2000-11-28 US claimed
EP-0937032-A1 SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 1999-08-25 EP claimed
WO-1998017627-A1 SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS WARNER-LAMBERT COMPANY (US) 1998-04-30 WO claimed
EP-0937032-B1 SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS WARNER LAMBERT CO (US) 2007-05-09 EP disclosed
US-6153650-A TREATMENT OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, NEUROPATHOLOGICAL DISORDERS, INFLAMMATION, AND GASTROINTESTINAL DAMAGE. WARNER-LAMBERT COMPANY (US) 2000-11-28 US disclosed
EP-0937032-A1 SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 1999-08-25 EP disclosed
WO-1998017627-A1 SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS WARNER-LAMBERT COMPANY (US) 1998-04-30 WO disclosed